Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Acceleron Pharma IncfiledCriticalCelgene Corp
Publication of AR104621A1publicationCriticalpatent/AR104621A1/es
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Métodos de tratamiento de la b-talasemia por medio de la administración subcutánea de aproximadamente 0,8 mg/kg de un inhibidor de la señalización de ActRII. Métodos de ajuste de la dosis del inhibidor de la señalización de ActRII administrada al sujeto.
ARP160101392A2015-05-132016-05-12TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII
AR104621A1
(es)
Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical com¬position, medicinal prepara¬tion, method for treating prostate cancer